NASDAQIndustrialsAerospace & DefenseSnapshot 2026-08-31
Reading ARXS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Aerospace & Defense is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 2% a day.
View RiskMostly healthy — no soft spokes
ARXS's growth through strategic acquisitions has to keep compounding to justify the price. Revenue grew 25% year over year, and the last quarter beat expectations. It trades at 12× price-to-sales versus a peer median of 4×. The price reflects less growth than forecast, indicating modest expectations. If ARXS reverses and cuts guidance after recently raising, that would hurt credibility. Peer multiples imply a price about 17% below where it trades (it looks expensive on this basis). This read is provisional.
Trailing returns as of 2026-08-31. ARXS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 11 analysts currently covering ARXS (as of Aug 2026).
Based on 9 Wall Street analysts offering 12-month price targets for ARXS in the last 4 months.
A consensus fair price across 5 valuation methods, at three horizons. As of 2026-08-31. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Aerospace & Defense — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Advances: Growth through strategic acquisitions
Acquisition aligns with growth strategy and enhances market position.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-08-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $51.77
The last 12 months of price, then the range of analyst 12-month targets from today’s $51.77.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Advances: Growth through strategic acquisitions
Acquisition aligns with growth through strategic acquisitions objective.
Advances: Growth through strategic acquisitions
Acquisitions support growth strategy and expand market presence.
Advances: Achieve full-year 2026 revenue guidance of $1.86B to $1.88B
Record results and guidance support revenue targets for 2026.
Advances: Achieve full-year 2026 revenue guidance of $1.86B to $1.88B
Positive guidance reinforces confidence in achieving revenue goals.
Acquisition aligns with growth through strategic acquisitions objective.
Acquisition supports growth through strategic acquisitions objective.
Acquisition supports growth through strategic acquisitions objective.
